Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer
and the third leading cause of cancer mortality worldwide. The development of effective …

Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Background Whether pembrolizumab given both before surgery (neoadjuvant therapy) and
after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant …

BACKGROUND: Phase 1-2 trials involving patients with resectable, macroscopic stage III
melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Background Neoadjuvant chemotherapy and radiation followed by surgical resection of the
rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is …

Although immunotherapy research to date has focused largely on T cells, there is mounting
evidence that tumour-infiltrating B cells and plasma cells (collectively referred to as tumour …

Tumour-infiltrating lymphocytes (TILs) are considered crucial in anti-tumour immunity.
Accordingly, the presence of TILs contains prognostic and predictive value. In 2011, we …

Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in
clinical stage III nodal melanoma, and pathologic response is strongly associated with …

RNA sequencing (RNAseq) can reveal gene fusions, splicing variants, mutations/indels in
addition to differential gene expression, thus providing a more complete genetic picture than …